Eric Van Cutsem

Specialty: Digestive Oncology

Location: Unknown

Tier: ELITE

H-Index: 190

Years Active: 0

Hospital Affiliations

• KU Leuven - Faculty

Key Publications

1. "Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial." - Nat Med (2023)
2. "MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer." - Future Oncol (2022)
3. "Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial." - Lancet (2023)
4. "Pembrolizumab in HER2-Positive Gastric Cancer." - N Engl J Med (2024)
5. "Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer." - N Engl J Med (2024)

Knowledge Graph Relationships

Eric Van Cutsem is a Digestive Oncology specialist affiliated with KU Leuven. Authored 5 scholarly articles.